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Background and Aims: Chemotherapy-induced acute and delayed emesis involves
the activation of multiple pathways, with 5-hydroxytryptamine (5-HT; serotonin) playing
a major role in the initial response. Substance P tachykinin NK1 receptor antagonists
can reduce emesis induced by disparate emetic challenges and therefore have a clinical
utility as broad inhibitory anti-emetic drugs. In the present studies, we investigate
the broad inhibitory anti-emetic profile of a relatively new NK1 receptor antagonist,
netupitant, alone or in combination with the long acting 5-HT3 receptor antagonist,
palonosetron, for a potential to reduce emesis in ferrets and shrews.
Materials and Methods: Ferrets were pretreated with netupitant and/or palonosetron,
and then administered apomorphine (0.125 mg/kg, s.c.), morphine (0.5 mg/kg, s.c.),
ipecacuanha (1.2 mg/kg, p.o.), copper sulfate (100 mg/kg, intragastric), or cisplatin (5–
10 mg/kg, i.p.); in other studies netupitant was administered to Suncus murinus before
motion (4 cm horizontal displacement, 2 Hz for 10 min).
Results: Netupitant (3 mg/kg, p.o.) abolished apomorphine-, morphine-, ipecacuanha-
and copper sulfate-induced emesis. Lower doses of netupitant (0.03–0.3 mg/kg, p.o.)
dose-dependently reduced cisplatin (10 mg/kg, i.p.)-induced emesis in an acute (8 h)
model, and motion-induced emesis in S. murinus. In a ferret cisplatin (5 mg/kg, i.p.)-
induced acute and delayed emesis model, netupitant administered once at 3 mg/kg,
p.o., abolished the first 24 h response and reduced the 24–72 h response by 94.6%;
the reduction was markedly superior to the effect of a three times per day administration
of ondansetron (1 mg/kg, i.p.). A single administration of netupitant (1 mg/kg, p.o.)
plus palonosetron (0.1 mg/kg, p.o.) combined with dexamethasone (1 mg/kg, i.p.,
once per day), also significantly antagonized cisplatin-induced acute and delayed
emesis and was comparable with a once-daily regimen of ondansetron (1 mg/kg, p.o.)
plus aprepitant (1 mg/kg, p.o.) in combination with dexamethasone (1 mg/kg, i.p.).
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Conclusion: In conclusion, netupitant has potent and long lasting anti-emetic activity
against a number of emetic challenges indicating broad inhibitory properties. The
convenience of protection afforded by the single dosing of netupitant together with
palonosetron was demonstrated and also is known to provide an advantage over other
therapeutic strategies to control emesis in man.
Keywords: anti-emetic, nausea, vomiting, chemotherapy, 5-HT3, NK1, ferret
INTRODUCTION
The treatment of cancer with chemotherapeutic agents such as
cisplatin is documented to be associated with a number of side
effects including nausea and emesis, which can be reduced by
agents blocking 5-HT3 and substance P NK1 receptors (Rudd
and Andrews, 2004; Hesketh, 2008). It has been hypothesized
that there is an initial release of 5-HT (serotonin) from
enterochromaffin cells in the gastrointestinal tract to activate
5-HT3 receptors located on vagal afferents (Naylor and Rudd,
1996; Minami et al., 2003). The mechanism of release is not
entirely known but may involve free radical generation and/or
cellular damage, which subsequently leads to the involvement of
other neurotransmitter systems and/or mediators (Andrews and
Rudd, 2015). The response occurring over the first 0–24 h has
become known as the acute response, and ‘first generation’ 5-HT3
receptor antagonists, such as ondansetron and granisetron, have
been used widely to reduce nausea and emesis during this phase
(Hesketh, 2008). However, 5-HT3 receptor antagonists are less
effective to control nausea and emesis occurring during the post
24 h period, which became known as the delayed phase of emesis
(Rudd and Andrews, 2004).
To improve the overall control of acute and delayed
emesis, 5-HT3 receptor antagonists were initially combined with
glucocorticoids such as dexamethasone (Hesketh et al., 1994;
Ioannidis et al., 2000). Subsequently, preclinical studies identified
that brain penetrating tachykinin NK1 receptor antagonists had
a broad inhibitory profile to inhibit emesis induced by disparate
challenges (Bountra et al., 1993; Tattersall et al., 1993, 1994;
Andrews and Rudd, 2004). It was also shown that NK1 receptor
antagonists had anti-emetic activity in a ferret model of acute
and delayed emesis prompting clinical testing (Rudd et al.,
1996; Singh et al., 1997; Tattersall et al., 2000; Tsuchiya et al.,
2002). The standard regimen to control both phases of emesis
in man quickly changed to a triple regimen of a 5-HT3 receptor
antagonist, in combination with the first licensed NK1 receptor
antagonist for chemotherapy-induced emesis, aprepitant, plus a
glucocorticoid (Jordan et al., 2005; Roila et al., 2010; Bayo et al.,
2012). Unfortunately, however, even with these advances, there
still remains a proportion of patients not adequately protected
from chemotherapy-induced nausea and emesis (Navari, 2004;
Aranda Aguilar et al., 2005).
Palonosetron is a ‘second generation’ 5-HT3 receptor
antagonist that is an order of magnitude more potent than
older compounds at blocking 5-HT3 receptors and has excellent
bioavailability following oral administration (F 99%); it also has a
plasma half-life that is approximately three times longer, enabling
a convenient once per day administration (Wong et al., 1995;
Grunberg and Koeller, 2003; De Leon, 2006). In the clinical
setting, palonosetron was shown to be superior to the first
generation 5-HT3 receptor antagonists, particularly in its ability
to reduce delayed nausea and emesis (Rubenstein, 2004; Geling
and Eichler, 2005; Tonini et al., 2005). It was speculated that the
unique profile of palonosetron may relate to its additional ability
to prevent 5-HT3 receptor re-cycling and/or a potential to reduce
substance P responses mediated via NK1 receptors by preventing
5-HT3 and NK1 receptor cross-talk (Rojas et al., 2008, 2010b,
2014; Stathis et al., 2012).
Since the clinical introduction of aprepitant, there have also
been advances in the design of more potent and longer acting
tachykinin NK1 receptor antagonists (Reddy et al., 2006; Rojas
et al., 2014). Netupitant is a novel orally active compound
that penetrates into the brain and has a long duration of
action and an insurmountable blocking activity at NK1 receptors
(Rizzi et al., 2012). Studies using NG108-15 cells have shown
that netupitant and palonosetron have synergistic effects to
antagonize substance P-induced calcium mobilization; synergism
was not seen when netupitant was combined with ondansetron
or granisetron (Stathis et al., 2012). Clinically, netupitant plus
dexamethasone was shown to be superior to palonosetron plus
dexamethasone against moderately emetogenic chemotherapy
(Aapro et al., 2014), but the combination of netupitant and
palonosetron with dexamethasone provided an excellent control
of highly emetogenic chemotherapy induced-acute and delayed
emesis, showing improvements over ondansetron and aprepitant
combinations, with efficacy being maintained over multiple
cycles (Gralla et al., 2014; Hesketh et al., 2014; Navari, 2015).
In the present studies, we used the ferret, a species with
proven translational value in anti-emetic research (Percie du Sert
et al., 2011), to explore the potential of a single administration of
netupitant alone or in combination with palonosetron to inhibit
cisplatin-induced acute and delayed emesis following an oral
administration, compared with the control of emesis afforded by
the three times per day administration of ondansetron alone, or
when ondansetron was used daily combined with aprepitant and
dexamethasone (Tattersall et al., 2000). An attempt was also made
to characterize the spectrum of anti-emetic activity of netupitant
to reduce emesis induced by other challenges. Apomorphine and
morphine were selected to induce emesis via the area postrema
(Lau et al., 2005; Percie du Sert et al., 2009), and intragastric
copper sulfate was chosen to induce emesis via peripheral vagal
and splanchnic pathways from the gastrointestinal tract (Kan
et al., 2006). Ipecacuanha was selected as an emetogen inducing
emesis via mixed central and peripheral pathways (Ariumi et al.,
2000; Hasegawa et al., 2002). We also utilized Suncus murinus
(house musk shrew) to investigate the potential of netupitant to
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reduce provocative motion-induced emesis that involves central
pathways via vestibular inputs (Ueno et al., 1988; Ito et al., 2003).
The studies described represent a reference point for others to
compare the anti-emetic activity of new chemical entities or
therapeutic strategies for the treatment of emesis.
MATERIALS AND METHODS
Animals
Male castrated ferrets (0.8–1.8 kg) were obtained from the
University of Leeds (England) or Southland Ferrets (Invercargill,
New Zealand). Water and food (SDS Diet ‘C,’ Special Diet
Services, Ltd., UK, or TriPro super premium chicken meal
formula dog food, American Nutrition, USA) were given ad
libitum unless otherwise stated. Male S. murinus (45–65 g) were
obtained from the University of Bradford (Bradford, U.K.). Dry
pelleted trout pellets (Aquatic 3, Special Diet Services, UK) and
water were given ad libitum unless otherwise stated. Animals
were housed in temperature-controlled rooms at 20–24± 1◦C
under artificial lighting, with lights on between 06:00 and
18:00 h. The relative humidity was maintained at 50 ± 5%. All
experiments were conducted under license from the respective
Governments of England, Switzerland and Hong Kong, and
were approved by the relevant Animal Experimentation Ethics
committees.
Determination of the Plasma Half-Life of
Netupitant in Ferrets
Ferrets were anesthetized with halothane (3%) in oxygen and the
left jugular vein was cannulated and exteriorized to the back of
the neck using standard surgical techniques (Barnes et al., 1991).
Animals were then allowed to recover for 2 weeks. On the day of
the experiment, at t = 0, a 1.5 ml blood sample was withdrawn
before administering netupitant (3 mg/kg, p.o.). Subsequently,
further blood sampling (1.5 ml) was continued at 1, 3, 6, 12,
24, 36, 48, 60, 72, 84, and 96 h. Each sample was centrifuged at
10,000 g for 10 min and the plasma was stored at −80◦C prior
to analysis. The analytical method used to determine the plasma
concentration of netupitant was essentially the same as described
by Huskey et al. (2003).
Experiments in Ferrets Involving
Apomorphine, Morphine, Ipecacuanha,
and Cisplatin during Acute Observation
Times
On the day of experiment, the animals were transferred to
individual cages where they were allowed at least 30 min to
adapt before being presented with approximately 100 g of food.
Netupitant (0.03–3 mg/kg) or vehicle [0.3% (v/v) Tween 80 in
saline; 2 ml/kg] was then administered orally 2 h before the
subcutaneous administration of apomorphine (0.125 mg/kg, s.c.),
morphine (0.5 mg/kg, s.c.), ipecacuanha (1.2 mg/kg, p.o.), copper
sulfate (100 mg/kg, i.g.), or cisplatin (10 mg/kg, i.p.). Animal
behavior was recorded for up to 8 h using a closed circuit video
recording system.
Experiments Involving Suncus murinus
and Provocative Motion
The protocol used for the provocative motion-induced emesis
experiments have been described previously (Chan et al., 2007).
Briefly, the animals were transferred to the behavioral laboratory
and given 30 min to habituate before being administered
netupitant (0.03–3 mg/kg) or vehicle [0.3% (v/v) Tween 80 in
saline; 2 ml/kg] orally. After 105 min, they were transferred to
individual chambers (21 cm× 14 cm× 13 cm) and given 15 min
to adapt before starting the provocative motion stimulus (i.e.,
120 min post netupitant/vehicle administration; 4 cm horizontal
displacement, 2 Hz, using a Heidolph Promax 2020 desktop
shaker, Labplant, England). Animal behavior was recorded for
10 min using a closed circuit video recording system (Chan et al.,
2007).
Experiments to Assess Anti-Emetic
Potency on Cisplatin-Induced Acute and
Delayed Emesis
The ferret acute and delayed emesis model has been described
previously (Rudd and Naylor, 1996). Animals were transferred
to individual observation cages where they were allowed at least
48 h to adapt. A dry pellet diet (Laboratory Feline Diet 5003,
PMI Nutrition Inc., St. Louis, MO, USA) and water was available
ad libitum. Animals were presented with 100 g of commercially
available cat food (Whiskas R©, Effem Foods Pty. Ltd., Wodonga,
Australia) 30 min prior to drug/vehicle administration. In an
initial series of experiments, ferrets were administered with
cisplatin (5 mg/kg) intraperitoneally followed immediately by the
oral administration of vehicle [0.3% (v/v) Tween 80 in saline;
2 ml/kg], netupitant (1–3 mg/kg), or ondansetron (1 mg/kg); the
administration of vehicle or ondansetron was repeated at 8 h
intervals.
In other experiments, ferrets were allowed a 2-day habituation
period. Some ferrets were administered ondansetron (1 mg/kg,
p.o.), or netupitant (3 mg/kg, p.o.), 2 h prior to the administration
of cisplatin (5 mg/kg, i.p.); the administration of ondansetron
was repeated at 8 h intervals. In other experiments, ferrets were
administered palonosetron (0.1 mg/kg, p.o.) and/or netupitant
(1 mg/kg, p.o.), in combination with dexamethasone (1 mg/kg,
i.p.), or respective vehicles (2 ml/kg) 15 min before cisplatin
(5 mg/kg, i.p.); dexamethasone (1 mg/kg, i.p.) or vehicle (distilled
water, 1 ml/kg) was administered 15 min before cisplatin
(5 mg/kg, i.p.) and then repeated at 24 h intervals. Some animals
were also randomized as positive controls and administered
ondansetron (1 mg/kg, p.o.) plus aprepitant (1 mg/kg, p.o.)
orally 15 min before cisplatin and dexamethasone (1 mg/kg,
i.p.) 15 min before cisplatin; ondansetron, and dexamethasone
administrations were repeated at 24 h intervals. Respective
vehicle controls (distilled water, 2 ml/kg) were also utilized.
Measurement of Emesis
Emesis was characterized by rhythmic abdominal contractions
that were either associated with the forceful oral expulsion
of solid or liquid material from the gastrointestinal tract (i.e.,
vomiting), or not associated with the passage of material
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TABLE 1 | Ability of netupitant to abolish retching and vomiting induced by apomorphine, morphine, ipecacuanha, and copper sulfate pentahydrate.
Treatment Apomorphine
(0.125 mg/kg, s.c.)
Morphine
(0.5 mg/kg, s.c.)
Ipecacuanha
(1.2 mg/kg, p.o.)
Copper Sulphate
(100 mg/kg, intragastric)
Vehicle 26.2 ± 2.8 43.8 ± 3.7 37.5 ± 6.8 78.8 ± 6.5
Netupitant 3 mg/kg, p.o. 0.0 ± 0.0∗∗ 0.0 ± 0.0∗∗ 0.0 ± 0.0∗∗ 0.0 ± 0.0∗∗
Netupitant (3 mg/kg) or vehicle, was administered orally 2 h prior to challenge with emetic drugs. Data represents the mean ± SEM of the number of retches + vomits
recorded during a 30–60 min observation period. Significant differences relative to the vehicle control treated animals are indicated as ∗∗P < 0.01 (Student’s unpaired
t-test; n = 6).
(i.e., retching movements). For ferrets, consecutive episodes of
retching and/or vomiting were considered separate when the
animal changed its location in the observation cage, or when
the interval between episodes exceeded 5 s (Rudd and Naylor,
1996). For S. murinus, episodes of emesis were also characterized
as described above, except that the interval to demarcate two
consecutive episodes of retching and/or vomiting was 2 s (Rudd
et al., 1999). At the end of the observation period, animals were
terminated by an intraperitoneal injection of pentobarbitone
sodium (80 mg/kg).
Data Analysis
Data are expressed as the mean ± SEM, unless otherwise
stated. Half-life values and ID50 values were calculated from
data expressed as a percentage of the control response using
linear and non-linear regression analysis, respectively. In all
cases, differences between treatment groups were considered
significant when P < 0.05 (Student’s T-test, or one way ANOVA
and Tukey’s multiple comparison tests, as appropriate; GraphPad
Prism version 5.0, Inc. Version, San Diego, CA, USA).
Drug Formulation
Ondansetron hydrochloride d-hydrate, dexamethasone
21-phosphate disodium salt, and D-mannitol were from
Sigma–Aldrich, St. Louis, MO, USA. Cisplatin (1 mg/ml in 0.1%
mannitol in saline) was from David Bull Laboratories, Mulgrave,
VIC, Australia. Palonosetron hydrochloride, aprepitant
and netupitant were from Helsinn Advanced Synthesis SA,
Switzerland. Ondansetron, dexamethasone, and palonosetron
were dissolved in distilled water. Netupitant was dissolved in
0.3% Tween 80 in Saline (0.9% w/v). Aprepitant was dissolved in
a solution of ethanol:propylene glycol:distilled water in the ratio
of 1:6:3. Doses are expressed as the free base and dosing volumes
were 1 ml/kg.
RESULTS
Pharmacokinetic Profile of Netupitant in
Ferrets
The plasma level of netupitant peaked 1–3 h following its oral
administration; the Tmax was 2.5 ± 0.5 h and the Cmax was
397.3 ± 19.7 ng/ml (n = 4). The plasma level of netupitant was
measurable up to 96 h and had a flat terminal profile with a
terminal half-life of 78.5± 17.0 h (n= 4).
Anti-Emetic of Activity of Netupitant
against Drug- and Motion-Induced
Emesis in the Ferret
No retching or vomiting was observed during the habituation
periods and there were no obvious differences in the behavior
of the animals randomized to the treatment groups prior
to drug/vehicle administration. Netupitant was not associated
with emesis during the pre-treatment period. Apomorphine,
morphine and copper sulfate subsequently induced emesis in the
vehicle treated animals following a short latency of ∼ 5 min
(data not shown). The range of retches + vomits recorded
during the 30 min observation periods were: apomorphine,
21–35; morphine, 33–55; and copper sulfate, 60–100. The oral
administration of netupitant at 3 mg/kg completely prevented the
retching and vomiting response to these challenges (P < 0.01;
Table 1). A more detailed dose-ranging experiment against
apomorphine (control retches + vomits range: 17–32) revealed
that a significant 33.8% reduction of retching + vomiting
could be observed at doses of netupitant as low as 0.03 mg/kg
(P < 0.05); increasing the doses to 0.1 mg/kg reduced emesis by
75.6% (P < 0.01) and 0.3 mg/kg prevented emesis completely
(P < 0.01; Figure 1). The ID50 to inhibit apomorphine-induced
retching + vomiting was 0.08 mg/kg, p.o. In the experiments
involving ipecacuanha, the vehicle treated control animals
exhibited emesis following a latency period of approximately
20 min (data not shown) that comprised ∼38 retches + vomits
during the 60 min observation period. The emetic response
induced by ipecacuanha was similarly prevented completely by
netupitant at 3 mg/kg, p.o. (P < 0.05; Table 1). No dose-ranging
experiments were done against ipecacuanha, copper sulfate or
morphine, so ID50 values could not be calculated.
In the experiments involving the use of cisplatin at 10 mg/kg,
i.p., the vehicle treated control animals exhibited emesis after
60–90 min that comprised ∼145 retches + vomits (range:
103–173) during the 8 h observation period. Netupitant at
0.1 mg/kg antagonized significantly the retching + vomiting
response by 27.1% (P < 0.05) and increasing the dose of
netupitant to 0.3 mg/kg, p.o., antagonized the response by 95.2%
(Figure 2; P< 0.01); the ID50 to inhibit emesis was approximately
0.1 mg/kg, p.o.
Anti-Emetic of Activity of Netupitant
against Provocative Motion (4 cm
Horizontal Displacement at 2 Hz for
10 min)-Induced Emesis
In the experiments involving provocative motion, five out of six
vehicle treated control animals exhibited emesis after a short
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FIGURE 1 | The effect of netupitant on (A) apomorphine (0.125 mg/kg,
s.c.)-induced emesis in ferrets and (B) motion-induced emesis in
Suncus murinus. Netupitant (0.03–0.3 mg/kg) or vehicle was administered
orally 2 h prior to apomorphine (0.125 mg/kg, s.c.) or motion (4 cm horizontal
displacement, 2 Hz for 10 min). Significant differences relative to vehicle
treated animals (0 mg/kg) are indicated as ∗P < 0.05 or ∗∗P < 0.01 (one way
ANOVA followed by Tukey’s multiple comparison testing).
latency (∼2–4 min) that comprised ∼8 retches + vomits (range:
7–11) during the 10 min observation period. Netupitant at
0.1 mg/kg, p.o. antagonized significantly the retching+ vomiting
response by 75.6% (P < 0.01), and increasing the dose of
netupitant to 0.3 mg/kg, p.o., prevented the response completely
(Figure 1; P < 0.01); the ID50 to inhibit emesis was 0.08 mg/kg,
p.o.
Anti-Emetic Potential of Netupitant
Compared with Ondansetron to Inhibit
Cisplatin (5 mg/kg, i.p.)-Induced Acute
and Delayed Emesis
In vehicle treated animals, cisplatin induced 148.7 ± 11.5 and
242.2 ± 24.0 retches + vomits during the acute (0–24 h) and
delayed (24-3-72 h) periods, respectively (Figure 3). The three
times per day administration of ondansetron, 1 mg/kg, p.o.,
reduced the acute response significantly by 67.8% (P < 0.01) and
also reduced the delayed response by 48.3% (P < 0.01; Figure 3).
Netupitant at 3 mg/kg, p.o., administered 2 h prior to the
injection of cisplatin, prevented completely the acute response
FIGURE 2 | The effect of netupitant on cisplatin
(10 mg/kg, i.p.)-induced emesis in ferret. Netupitant (0.03–0.3 mg/kg) or
vehicle was administered orally 2 h prior to cisplatin (10 mg/kg, i.p.; t = 0).
Data represents the mean ± SEM of (A) cumulative numbers of
retches + vomits per 30 min, or (B) the total numbers of retches + vomits
occurring over 8 h (n = 5–6). Significant differences relative to vehicle treated
animals (0 mg/kg) are indicated as ∗P < 0.05, ∗∗P < 0.01 (one way ANOVA
followed by Tukey’s multiple comparison testing).
(P < 0.05) and reduced the delayed response significantly by
94.6% (P < 0.01; Figure 3). In fact, the single administration
of netupitant was almost twice as effective as the three times
administration of ondansetron to prevent the acute and delayed
retching and vomiting response (P < 0.01; Figure 3).
Comparison of the Anti-Emetic Activity
of the Once Only Administration of
Palonosetron and Netupitant with the
Standard Regimen of Ondansetron and
Aprepitant
In vehicle treated animals, cisplatin induced 205.6 ± 40.5 and
471.0 ± 98.3 retches + vomits during the acute (0–24 h)
and delayed (24–72 h) periods, respectively (Figure 4). Both
the standard regimen of ondansetron (1 mg/kg, p.o., every
24 h) plus aprepitant (1 mg/kg, p.o., administered once) and
dexamethasone (1 mg/kg, i.p., every 24 h), and the single
administration of netupitant (1 mg/kg, p.o.) plus palonosetron
(0.1 mg/kg, p.o.) in combination with daily dexamethasone
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FIGURE 3 | The effect of ondansetron (O1) or netupitant (N3) on the profile of retching and/or vomiting induced by cisplatin in the ferret. Ondansetron,
(1 mg/kg, p.o.), was administered 15 min before cisplatin (5 mg/kg, i.p.; t = 0) and then at regular 8 h intervals; netupitant (3 mg/kg, p.o.) was administered once,
2 h prior to cisplatin. Data represents the mean ± SEM of the total numbers of retches + vomits occurring in (A) 1, (B) 0–24, or (C) 24–72 h time intervals, as
appropriate (n = 5–6). Significant differences relative to vehicle treated animals (V) are indicated as ∗∗P < 0.01; significant differences relative to ondansetron treated
animals are indicated as ††P < 0.01 (one way ANOVA followed by Tukey’s multiple comparison testing).
(1 mg/kg, i.p.) were highly effective to reduce the acute response
significantly by 99.7 (P< 0.01) and 97.3% (P< 0.01), respectively
(Figure 4). The standard regimen of ondansetron plus aprepitant
and dexamethasone also reduced significantly the delayed emetic
response by 86.3% (P < 0.01). The netupitant plus palonosetron
and dexamethasone regimen reduced delayed emesis to a lesser
extent by 60.2% (P < 0.05). However, there were no significant
differences in the control of acute or delayed emesis by the two
anti-emetic regimens (P > 0.05).
DISCUSSION
Netupitant was orally active to antagonize emesis induced by
diverse emetogenic stimuli in ferrets and S. murinus. This
profile is consistent with other NK1 receptor antagonists that
are presumed to be capable of penetrating the blood brain
barrier to reach sites in the dorsal vagal complex and/or sites
thought to be adjacent to the semi-compact part of the nucleus
ambiguous (Tattersall et al., 1996; Fukuda et al., 1999; Andrews
and Rudd, 2004). This is particularly relevant for centrally acting
emetogens, such as apomorphine and morphine, or motion, but
for other stimuli that may also cause a release of substance P
in the periphery, the mechanism may in part also involve NK1
receptors on the vagus or perhaps those located elsewhere in the
periphery (Minami et al., 1998; Darmani et al., 2008; Ray et al.,
2009).
The broad inhibitory anti-emetic profile in ferrets
encompassed five challenges where acute emesis was induced:
apomorphine [mechanism involving D2 receptors at the level
of the area postrema; (Lau et al., 2005)], morphine [emetic
mechanism involving opioid receptors at the level of the area
postrema; (Rudd and Naylor, 1995; Percie du Sert et al., 2009)],
copper sulfate [mechanism predominantly involving gastric
irritation and vagal and/or splanchnic nerves, but where the
transmitter systems are not completely characterized; (Makale
and King, 1992; Kan et al., 2006)], ipecacuanha [mechanism
involving 5-HT3 receptors and vagal and/or splanchnic nerves;
(Ariumi et al., 2000; Hasegawa et al., 2002)] and cisplatin
[high-dose model – mechanism involving a release of 5-HT
from enterochromaffin cells, 5-HT3 receptors and vagal and/or
splanchnic nerves and activation of the area postrema; (Percie
du Sert et al., 2009)]. Several doses of netupitant were utilized
to compare potency to inhibit apomorphine- and cisplatin-
induced emesis yielding ID50 values of ∼0.1 mg/kg, p.o., which
is five times below its reported potency in the gerbil foot
tapping assay [ID50 = 0.5 mg/kg, p.o.; (Rizzi et al., 2012)]; at
0.3 mg/kg netupitant inhibited the emetic responses completely.
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FIGURE 4 | A comparison of the effect of ondansetron plus aprepitant in combination with dexamethasone (O+A+D) with netupitant plus
palonosetron in combination with dexamethasone (N1+P0.1+D) on cisplatin-induced retching and/or vomiting. Ondansetron, (1 mg/kg, p.o.), aprepitant
(1 mg/kg, p.o.), palonosetron (0.1 mg/kg, p.o.), netupitant (1 mg/kg, p.o.), or dexamethasone (1 mg/kg, i.p.), or vehicle, were administered 15 min before cisplatin
(5 mg/kg, i.p.; t = 0); the administration of ondansetron (1 mg/kg, p.o.) or dexamethasone (1 mg/kg, i.p.) or vehicle was repeated at 24 h intervals. Data represents
the mean ± SEM of the total numbers of retches + vomits occurring in (A) 1, (B) 0–24, or (C) 24–72 h time intervals, as appropriate (n = 5–6). Significant differences
relative to vehicle treated animals (V+V+V) are indicated as ∗P < 0.05, or ∗∗P < 0.01 (one way ANOVA followed by Tukey’s multiple comparison testing).
A remarkably similar relative potency difference of other NK1
receptor antagonists in the ferret cisplatin-induced emesis
assay and the gerbil foot-tapping assay has been reported
following intravenously administered brain penetrating NK1
receptor antagonists, GR203040, CP-99,994, and L-742,694
(ID50 values in foot taping assay ∼0.85 mg/kg; ID50 values
in the cisplatin assay were ∼0.18 mg/kg; Rupniak et al.,
1997). The consistency of relative potency of the antagonists
between studies may reflect netupitant’s excellent bioavailability
following oral administration (present investigations). It is
also relevant that netupitant binds with high affinity to human
NK1 receptors (pKi = 9.0), with 1,000 fold selectivity over
other tachykinin and G-protein coupled receptors (Rizzi
et al., 2012). Predictably, in our studies, the use of netupitant
at 3 mg/kg, p.o., abolished morphine- and ipecacuanha-
induced emesis; a similar spectrum of effects has been
reported for several other NK1 receptor antagonists against
these emetic stimuli [for a review, see (Andrews and Rudd,
2004)].
We also explored the anti-emetic potential of netupitant in the
ferret cisplatin (low-dose 5 mg/kg)-induced acute and delayed
emesis model (Rudd et al., 1994; Rudd and Naylor, 1997; Sam
et al., 2001). In the present studies, the single oral administration
of netupitant at 3 mg/kg was shown to be far superior to the
three times per day administration of ondansetron (1 mg/kg,
i.p.) at antagonizing both the acute (netupitant abolished acute
emesis; ondansetron only reduced acute emesis by ∼68%) and
delayed response (netupitant reduced delayed emesis by ∼95%;
ondansetron reduced delayed emesis by ∼49%) to cisplatin; the
antagonism afforded by ondansetron is comparable to previously
published data in this species (Rudd and Naylor, 1994, 1997;
Rudd et al., 1996; Singh et al., 1997; Watanabe et al., 2008).
These data demonstrate that netupitant has an exceptionally long
duration of action which may relate to its exceptionally long
plasma half-life of ∼79 h (present studies), whereas the plasma
half-life of ondansetron is reported to be ∼2.3 h (Minami et al.,
1991). If we place this in perspective, the first NK1 receptor
antagonist tested in the ferret acute and delayed emesis model,
CP-99,994, [IC50 of 1.9 nM to displace [125I]-Bolton Hunter
Substance P from ferret brain membranes (Watson et al., 1995)],
had a short plasma half-life of ∼1.4 h [data from cat, (Lucot
et al., 1997)], and even when administered every 8 h at 10 mg/kg,
only reduced cisplatin-induced acute emesis by 34% and reduced
delayed emesis by ∼87% (Rudd et al., 1996); this was the dose
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of CP-99,994 that was also shown to prevent apomorphine,
morphine, ipecacuanha, cisplatin (high-dose)-induced emesis
(Bountra et al., 1993; Tattersall et al., 1993; Zaman et al., 2000).
Critically, aprepitant, which has an IC50 value of 0.7 nM at ferret
NK1 receptors (0.1 nM for human NK1 receptors), and plasma
half-life of 10 h [ferret; (Huskey et al., 2003); plasma half-life
in humans, 10–29 h; (Bubalo et al., 2012)], only produces a
similar level of inhibition of acute and delayed emesis when orally
administered at 16 mg/kg (Tattersall et al., 2000).
Palonosetron (RS 25259-197) was first described as a high
affinity 5-HT3 receptor antagonist [pKi ∼10; Wong et al.,
1995)] and was subsequently shown to have a plasma half-life
of ∼40 h in humans (Siddiqui and Scott, 2004; Stoltz et al.,
2004). It has been reported to inhibit cisplatin-induced emesis
(10 mg/kg, i.v.; 5 h test) in ferrets and dogs with ID50 values
of 0.003 and 0.008 mg/kg, respectively; the dose of 0.1 mg/kg,
p.o., inhibited emesis by almost 100% in both species (Eglen
et al., 1995). Indeed, palonosetron was revealed as being twice
as potent as ondansetron to inhibit cisplatin-induced emesis
in ferrets following oral administration (Eglen et al., 1995).
Clinically, palonosetron is recognized as being superior to other
5-HT3 receptor antagonists, particularly against chemotherapy-
induced delayed emesis (Navari, 2009; Saito et al., 2009). In
fact, the magnitude of difference, particularly in the control
of delayed emesis, was unexpected; prompting speculation that
palonosetron has properties distinct from other selective 5-HT3
receptor antagonists. There is strong evidence that it may have
a different mechanism of action to ondansetron at the 5-HT3
receptor, including an ability to cause receptor internalization,
with continued binding to the internalized receptor to prolong
the inhibition of its function (not seen with ondansetron
and granisetron) and, more recently, an indirect inhibition of
substance P responses, in vivo (Rojas et al., 2008, 2010a,b).
In the cisplatin (5 mg/kg, i.p.) acute and delayed emesis model,
we compared the anti-emetic potential of a regimen of netupitant
and palonosetron (both administered before cisplatin) in
combination with dexamethasone (administered before cisplatin
and then every 24 h), with a regimen comprising ondansetron
(administered before cisplatin and then every 24 h) and
aprepitant (administered once before cisplatin) in combination
with dexamethasone (administered before cisplatin and then
every 24 h). Both treatment regimens were highly effective to
antagonize acute emesis and were indistinguishable from each
other. Indeed, the anti-emetic effect of the regimen of netupitant
and palonosetron in combination with dexamethasone was still
evident during the delayed phase of the response, and was
not significantly different from the control of emesis seen
following the more frequent dosing regimen of ondansetron
and aprepitant in combination with dexamethasone. These data
compare favorably with previous studies investigating aprepitant,
ondansetron, and dexamethasone in ferrets (Tattersall et al.,
2000).
Palonosetron has also been studied in the Cryptotis parva
(least shrew). Across a subcutaneous dose range of 0.1–10 mg/kg,
palonosetron dose-dependently antagonized the emesis induced
by either the 5-HT3 receptor agonist, 2 methyl-5-HT (5 mg/kg),
i.p., or the L-type calcium channel opener, FLP 64176 (10 mg/kg,
i.p.; Darmani et al., 2014). It is unknown why palonosetron could
not completely inhibit 2-methyl-5-HT-induced emesis in this
species, but the level of inhibition was similar to that reported
for tropisetron against the same stimulus (Darmani, 1998).
Palonosetron administered as a single treatment, is not noted
to have a U-shaped dose-response curve in ferrets or man against
chemotherapy-induced emesis. However, in the least shrew,
palonosetron appears to have a species-specific biphasic anti-
emetic action against the initial 2 h of emesis induced by cisplatin
(10 mg/kg, i.p.), with a significant reduction at 0.1 and 2.5 mg/kg,
s.c; while at 0.5 and 5 mg/kg the protection was lost (Darmani
et al., 2014). In a subsequent set of experiments, palonosetron
was tested at 0.1 mg/kg, s.c., against the same dose of cisplatin
but over an extended observation period of 40 h (Darmani et al.,
2015). Palonosetron reduced the emesis occurring during the
initial first 16 h of the experiment by 83% compared to vehicle
pretreated cisplatin controls. An assessment of emesis during
the 27–40 h period also recorded a non-significant reduction
of 73% (Darmani et al., 2015). Comparatively, netupitant at a
high dose of 5 mg/kg, s.c., non-significantly reduced the emesis
occurring during the first 16 h by 70% and abolished emesis
during the 27–40 h period (Darmani et al., 2015). When both
palonosetron and netupitant were combined together, the emesis
occurring during the first 16 h was reduced by approximately
94%, and the reduction of emesis in the 27–40 h period was
still significantly reduced (Darmani et al., 2015). Thus, the
combination of palonosetron and netupitant resulted in a greater
level of protection against both acute and ‘delayed’ phases of
cisplatin-induced emesis in the least shrew than either treatment
administered alone.
Suncus murinus is a more commonly used shrew species
to study mechanisms of emesis, but its tachykinin receptor
has a distinct pharmacology compared to the human and
rodent NK1 receptor (Tattersall et al., 1995; Rudd et al., 1999).
However, in the present studies, netupitant dose-dependently
reduced motion-induced emesis, with a dose of 0.3 mg/kg,
p.o., preventing the response completely. In comparison with
data in the literature, netupitant appears more potent than
other NK1 receptor antagonists including CP-99,994, GR203040,
GR205171, and RP67580 to antagonize motion-induced emesis
in this species (Gardner et al., 1995, 1996; Rudd et al., 1999). It is
known that patients with a history of motion sickness also have a
higher incidence of chemotherapy-induced emesis (e.g., Morrow,
1984; Shih et al., 2009), post-operative nausea and vomiting,
and pregnancy sickness (Bouganim et al., 2012; Warr, 2014).
Therefore, it may be expected that netupitant would be useful
to control emesis in such patients, where pathways involving
motion sickness have been stimulated or perturbed.
CONCLUSION
The present studies revealed that netupitant has a broad
inhibitory profile to inhibit emesis both in ferrets and S. murinus.
In particular, a single dose of netupitant at 3 mg/kg given 3 h
prior to the administration of cisplatin, provided almost complete
Frontiers in Pharmacology | www.frontiersin.org 8 August 2016 | Volume 7 | Article 263
fphar-07-00263 August 29, 2016 Time: 12:37 # 9
Rudd et al. Netupitant and Chemotherapy-Induced Actue and Delayed Emesis
protection from acute and delayed emesis; a lower dose of
1 mg/kg, in combination with a single oral dose of palonosetron
at 0.1 mg/kg, in combination with daily administrations of
dexamethasone (1 mg/kg, i.p.), was also highly effective to reduce
acute and delayed emesis, being relatively comparable to a
more frequent dosing regimen of ondansetron plus aprepitant
in combination with dexamethasone. The convenience of oral
dosing, efficacy, and long duration of action are consistent
with clinical data. This has been realized by the successful
formulation and use of palonosetron plus netupitant in a single
pill (Akynzeo R©) for the treatment of chemotherapy-induced acute
and delayed nausea and emesis (Thompson, 2014; Lorusso et al.,
2015; Navari, 2015).
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